Extrahepatic Morbidity and Mortality of Chronic Hepatitis C
Top Cited Papers
- 1 November 2015
- journal article
- review article
- Published by Elsevier BV in Gastroenterology
- Vol. 149 (6), 1345-1360
- https://doi.org/10.1053/j.gastro.2015.08.035
Abstract
Chronic hepatitis C virus (HCV) infection is associated with several extrahepatic manifestations. Patients with HCV may develop mixed cryoglobulinemia and its sequelae, ranging from cutaneous and visceral vasculitis to glomerulonephritis and B-cell non-Hodgkin lymphoma. HCV-infected patients have increased rates of insulin resistance, diabetes, and atherosclerosis, which may lead to increased cardiovascular morbidity and mortality. Neurological manifestations of HCV infection include fatigue and cognitive impairment. The mechanisms causing the extrahepatic effects of HCV infection are likely multifactorial and may include endocrine effects, HCV replication in extrahepatic cells, or a heightened immune reaction with systemic effects. Successful eradication of HCV with interferon alfa and ribavirin was shown to improve some of these extrahepatic effects; sustained virological response is associated with resolution of complications of cryoglobulinemia, reduced levels of insulin resistance, reduced incidence of diabetes and stroke, and improved fatigue and cognitive functioning. The availability of new interferon-free, well-tolerated anti-HCV treatment regimens is broadening the spectrum of patients available for therapy, including those in whom interferon was contraindicated, and will likely result in greater improvements in the extrahepatic manifestations of HCV. If these regimens are shown to confer significant benefit in the metabolic, cardiovascular, or neuropsychiatric conditions associated with HCV infection, extrahepatic manifestations of HCV may become a major indication for treatment even in the absence of liver disease.This publication has 154 references indexed in Scilit:
- Therapy for Hepatitis C Virus–Related Cryoglobulinemic VasculitisNew England Journal of Medicine, 2013
- Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in TaiwanAlimentary Pharmacology & Therapeutics, 2013
- Cerebral Glucose Utilisation in Hepatitis C Virus Infection-Associated EncephalopathyJournal of Cerebral Blood Flow & Metabolism, 2011
- Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis CHepatology, 2009
- Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis CHepatology, 2008
- Hepatitis C infection and risk of diabetes: A systematic review and meta-analysisJournal of Hepatology, 2008
- Increased All-Cause, Liver, and Cardiac Mortality among Hepatitis C Virus-seropositive Blood DonorsAmerican Journal of Epidemiology, 2008
- Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parametersInternational Journal of Obesity, 2006
- IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicityMolecular Psychiatry, 2004
- Pruritus as a symptom of hepatitis CJournal of the American Academy of Dermatology, 1994